Percutaneous Microwave Ablation Yields 76% 10-Year Overall Survival for Renal Cell Carcinoma

Percutaneous MWA of T1 RCC showed 76% 10-year overall survival, 85% cancer-specific survival, and 83% local progression-free survival, with stable renal function and low complications.

• T1b tumors had lower 8-year local tumor progression-free survival than T1a (p=0.003).
• eGFR remained stable (58.5 vs 58.4 mL/min/1.73m²) 2–3 years post-ablation (p=0.932).
• Overall complication rate was 2%, all Clavien-Dindo grade I.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.